In addition, patients might have developed tolerance against their tumor cells not only by expression of PD1-PDL1, but also by other tolerance mechanisms - this could occur in patients who do not respond to anti-PDL1 therapy despite having PD1-PDL1 upregulated. Here, CD274 is linked to neoplasm.